Is ADC Therapeutics Stock a Good Investment?
ADC Therapeutics Investment Advice | ADCT |
- Examine ADC Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ADC Therapeutics' leadership team and their track record. Good management can help ADC Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Communications Equipment space and any emerging trends that could impact ADC Therapeutics' business and its evolving consumer preferences.
- Compare ADC Therapeutics' performance and market position to its competitors. Analyze how ADC Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if ADC Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ADC Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ADC Therapeutics SA stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ADC Therapeutics SA is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ADC Therapeutics Stock
Researching ADC Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 2.39. The entity had not issued any dividends in recent years.
To determine if ADC Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ADC Therapeutics' research are outlined below:
| ADC Therapeutics generated a negative expected return over the last 90 days | |
| ADC Therapeutics may become a speculative penny stock | |
| ADC Therapeutics has high historical volatility and very poor performance | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 69.56 M. Net Loss for the year was (240.05 M) with loss before overhead, payroll, taxes, and interest of (59.85 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (118.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are held by institutions such as insurance companies |
ADC Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ADC Therapeutics SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADC Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
ADC Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 159.54 M.ADC Therapeutics' profitablity analysis
The company has Profit Margin (PM) of (3.0) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.93) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.93.Determining ADC Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if ADC Therapeutics is a good buy. For example, gross profit margin measures ADC Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ADC Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ADC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADC Therapeutics SA. Check ADC Therapeutics' Beneish M Score to see the likelihood of ADC Therapeutics' management manipulating its earnings.
Basic technical analysis of ADC Stock
As of the 25th of March, ADC Therapeutics owns the variance of 24.05, and Market Risk Adjusted Performance of (0.22). ADC Therapeutics SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.ADC Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics' Outstanding Corporate Bonds
ADC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADC bonds can be classified according to their maturity, which is the date when ADC Therapeutics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand ADC Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ADC Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 4.01 | |||
| Coefficient Of Variation | (1,533) | |||
| Standard Deviation | 4.9 | |||
| Variance | 24.05 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 21.05 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 7.56 | |||
| Skewness | 0.4536 | |||
| Kurtosis | (0.20) |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 4.01 | |||
| Coefficient Of Variation | (1,533) | |||
| Standard Deviation | 4.9 | |||
| Variance | 24.05 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.33) | |||
| Total Risk Alpha | (0.35) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 21.05 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 7.56 | |||
| Skewness | 0.4536 | |||
| Kurtosis | (0.20) |
Consider ADC Therapeutics' intraday indicators
ADC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ADC Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 9047.75 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 1.63 | |||
| Day Typical Price | 1.62 | |||
| Price Action Indicator | (0.02) | |||
| Period Momentum Indicator | (0.03) |
ADC Stock media impact
Far too much social signal, news, headlines, and media speculation about ADC Therapeutics that are available to investors today. That information is available publicly through ADC media outlets and privately through word of mouth or via ADC internal channels. However, regardless of the origin, that massive amount of ADC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ADC Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ADC Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ADC Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ADC Therapeutics alpha.
ADC Therapeutics Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Thomas Pfisterer | Non-Executive Independent Director | Profile | |
| Tyrell Rivers | Non-Executive Independent Director | Profile | |
| Peter Hug | Non-Executive Independent Director | Profile |
Already Invested in ADC Therapeutics SA?
The danger of trading ADC Therapeutics SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.